Are diltiazem and amlodipine in the same subclass of calcium‑channel blockers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, diltiazem and amlodipine are NOT in the same subclass of calcium channel blockers.

Diltiazem is a benzothiazepine (non-dihydropyridine), while amlodipine is a dihydropyridine—these are distinct subclasses with different pharmacological properties and clinical effects 1, 2, 3.

The Three Subclasses of Calcium Channel Blockers

All calcium channel blockers share the same broad mechanism (blocking L-type calcium channels), but they are divided into three chemically and pharmacologically distinct subclasses:

1. Dihydropyridines (like amlodipine, nifedipine)

  • Primary effect: Marked peripheral arterial vasodilation
  • Cardiac effects: Minimal direct effects on heart rate or AV conduction
  • Clinical use: Hypertension, vasospastic angina
  • Key characteristic: May cause reflex tachycardia and peripheral edema 1, 4

2. Benzothiazepines (like diltiazem)

  • Primary effect: Moderate vasodilation (least among the three classes)
  • Cardiac effects: Significant negative chronotropic and dromotropic effects (slows heart rate and AV conduction)
  • Clinical use: Rate control, angina, hypertension
  • Key characteristic: Can be used for supraventricular arrhythmias 1, 5

3. Phenylalkylamines (like verapamil)

  • Primary effect: Similar to diltiazem but with more pronounced cardiac effects
  • Cardiac effects: Strong negative chronotropic, dromotropic, and inotropic effects
  • Clinical use: Rate control, supraventricular arrhythmias
  • Key characteristic: Can cause constipation; may induce AV block 1, 2

Critical Clinical Distinctions

The subclass matters significantly for patient selection:

  • Non-dihydropyridines (diltiazem, verapamil) should be avoided in patients with:

    • Significantly impaired left ventricular function 2, 6
    • Heart failure with reduced ejection fraction (due to negative inotropic effects) 6
    • AV conduction abnormalities without a pacemaker 7
  • Dihydropyridines (amlodipine, nifedipine) should not be used alone without concomitant beta-blocker therapy in acute coronary syndromes, as short-acting formulations may increase mortality 2, 7

Why This Distinction Matters

While both drugs block calcium channels and cause coronary vasodilation similarly 1, their divergent effects on cardiac conduction and contractility make them non-interchangeable in clinical practice. Diltiazem can control heart rate in atrial fibrillation; amlodipine cannot. Conversely, amlodipine is safe in heart failure with reduced ejection fraction; diltiazem is contraindicated 6.

Bottom line: Though both are "calcium channel blockers," diltiazem and amlodipine belong to different subclasses with distinct pharmacological profiles that dictate different clinical applications and contraindications.

Related Questions

What are the best calcium channel blockers (CCBs) for treating hypertension and angina?
Can a patient combine non-Dihydropyridine (non-DHP) Calcium Channel Blockers (CCBs) and Dihydropyridine (DHP) CCBs at the same time?
Can a patient with hypertension be on both verapamil (calcium channel blocker) and amlodipine (calcium channel blocker) simultaneously?
What is the difference between Dihydropyridine (DHP) and non-Dihydropyridine (non-DHP) calcium channel blockers in the management of hypertension or angina?
What are the adverse effects of Calcium Channel Blockers (CCBs)?
How should I manage a 40-year-old male with persistent ear fullness and reduced hearing after a recent otitis media, intermittent phantom TV-like noise, anxiety and depression not controlled on venlafaxine 75 mg, daily alprazolam use, and hypertension with elevated home blood pressures?
What is the appropriate evaluation and management for bronchial wall thickening in a former smoker?
Should I check serum ferritin and, if iron stores are adequate, increase oral elemental iron to 1200 mg per day for a patient who wishes to avoid opioid therapy?
Should metformin be initiated in a patient with type 2 diabetes, normal renal function (eGFR > 45 mL/min/1.73 m²), and no high risk for lactic acidosis to lower HbA1c and reduce insulin requirements?
How can I raise a patient's hemoglobin without adding iron?
What is the initial target arterial oxygen saturation for optimal neurological resuscitation after return of spontaneous circulation following cardiopulmonary resuscitation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.